Repare Therapeutics Inc.
RPTXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001808158
Repare Therapeutics Inc. was delisted in 2026; its insiders filed their last Form 4 on Jan 30, 2026; 46 institutions reported holding it in 13F filings for Q4 2025, worth $65.4M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 46
- Q4 2025, +2 vs. previous quarter
- 13F value
- $65.4M
- Reported value at the end of Q4 2025
- Superinvestors holding
- 0
- At the end of Q4 2025
Superinvestors holding RPTX, Q4 2025
No superinvestor reported holding RPTX at the end of Q4 2025.
Latest insider trades
Open-market purchases and sales by Repare Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 14, 2025 (view filing) | Mar 12 | 2 days | Koehler MariaEVP, CHIEF MEDICAL OFFICER | SSale | −3.60K | $1.14 | −$4.10K | −1.6%227.8K after | |
| Mar 14, 2025 (view filing) | Mar 12 | 2 days | Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICER | SSale | −5.61K | $1.14 | −$6.40K | −6.5%80.3K after | |
| Mar 14, 2025 (view filing) | Mar 12 | 2 days | Forte SteveEVP, CHIEF FINANCIAL OFFICER | SSale | −6.88K | $1.14 | −$7.85K | −11.2%54.8K after | |
| Mar 14, 2025 (view filing) | Mar 12 | 2 days | Segal Lloyd MitchellPRESIDENT AND CEO | SSale | −21.2K | $1.14 | −$24.1K | −14.5%124.4K after | |
| Apr 1, 2024 (view filing) | Mar 28-Apr 1 | 4 days | Segal Lloyd MitchellPRESIDENT AND CEO | SSale | −5.14K | $4.62 | −$23.8K | −4.6%107.6K after | 2 lots10b5-1 |
| Apr 1, 2024 (view filing) | Mar 28-Apr 1 | 4 days | Forte SteveEVP, CHIEF FINANCIAL OFFICER | SSale | −1.61K | $4.62 | −$7.45K | −3.5%44.8K after | 2 lots10b5-1 |
| Apr 1, 2024 (view filing) | Mar 28-Apr 1 | 4 days | Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICER | SSale | −860 | $4.65 | −$4.00K | −1.2%71.9K after | 2 lots10b5-1 |
| Apr 1, 2024 (view filing) | Mar 28-Apr 1 | 4 days | Koehler MariaEVP, CHIEF MEDICAL OFFICER | SSale | −800 | $4.65 | −$3.72K | −0.3%231.4K after | 2 lots10b5-1 |
| Mar 27, 2024 (view filing) | Mar 25-27 | 2 days | Forte SteveEVP, CHIEF FINANCIAL OFFICER | SSale | −2.48K | $4.67 | −$11.6K | −5.5%42.2K after | 3 lots10b5-1 |
| Mar 27, 2024 (view filing) | Mar 25-27 | 2 days | Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICER | SSale | −1.35K | $4.67 | −$6.30K | −1.8%72.8K after | 3 lots10b5-1 |
Top 10 13F holders, Q4 2025
The largest institutional positions in Repare Therapeutics Inc. at the end of Q4 2025; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 10,333,600 | $26.9M | 0.90% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 3,443,659 | $8.95M | 2.76% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 3,322,488 | $8.64M | 0.18% | 00.0% | Unchanged |
| Redmile Group, LLC | 1,586,174 | $4.12M | 0.30% | 00.0% | Unchanged |
| Rangeley Capital, LLC | 1,287,829 | $3.35M | 2.88% | +641,953+99.4% | Added |
| Marshall Wace, LLP | 1,115,744 | $2.90M | 0.00% | +1,115,744 | New |
| Renaissance Technologies LLC | 981,360 | $2.55M | 0.00% | +257,200+35.5% | Added |
| Acadian Asset Management LLC | 618,672 | $1.61M | 0.00% | +50,371+8.9% | Added |
| Two Sigma Investments, LP | 333,694 | $867.6K | 0.00% | +322,727+2,942.7% | Added |
| Jane Street Group, LLC | 278,304 | $723.6K | 0.00% | +278,304 | New |